CYTOKINE RELEASE SYNDROME (CRS) AND IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN LYMPHOMA PATIENTS RECEIVING AXICABTAGENE CILOLEUCEL: ANALYSIS BY YEAR OF TREATMENT AND INDICATIONS